EUVIMEDEUVIMED entdecken
Crossref

Quantitative dual-tracer 18F-FDG and 18F-DPA-714 PET/MR for characterizing pathological subtypes in refractory mesial temporal lobe epilepsy

Siqi Zhang, Xiaocao Liu, Bixiao Cui, Wenqi Xu, Chenyang Yao, Bin Wang, Liankun Ren, Jie Lu

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 7823-7834

DOI: 10.1007/s00259-026-08119-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 07.08.2026. Verfasst von Siqi Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Epilepsy, Temporal Lobe, Positron-Emission Tomography, Pyrimidines. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Huizhi Ascent Project of Xuanwu Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pathological subtypes are key determinants of surgical strategy and prognosis in refractory mesial temporal lobe epilepsy (MTLE), with hippocampal sclerosis (HS) associated with better outcomes than gliosis only. Subtype-specific patterns of cerebral metabolism and neuroinflammation, which may inform lesion localization and subtype differentiation, remain poorly defined. This study aimed to delineate these patterns using ¹⁸F-FDG PET and translocator protein (TSPO) PET with ¹⁸F-DPA-714 for precise localization, with emphasis on the added value of quantitative analysis. METHODS: Patients with unilateral refractory MTLE undergoing surgery were retrospectively included, and pathological subtypes were classified according to histological profiles (HS, n = 43; gliosis only, n = 41). Patients underwent sequential integrated dual-tracer PET/MR imaging within one week. Age- and sex-matched healthy controls (HC) were recruited. Whole-brain voxel-wise and temporal lobe subregional analyses were performed. Localization performance was assessed by visual inspection and quantitative analysis employing an asymmetry index (AI) derived from standardized uptake value ratios. Sensitivity and accuracy were calculated, with false discovery rate correction applied for multiple comparisons. RESULTS: In total, 43 MTLE-HS and 41 MTLE-gliosis only were included. Compared with HC, both HS and gliosis exhibited significant 18F-FDG hypometabolism alongside increased 18F-DPA-714 uptake, more pronounced in HS. Whole-brain 18F-DPA-714 abnormalities were more confined to temporal regions, affording clearer lateralization and localization than 18F-FDG. In temporal-lobe subregional analysis, 18F-FDG outperformed 18F-DPA-714 for subtype discrimination, and hippocampal AI value achieved the best performance (35/43 [81.4%] vs. 22/41 [53.7%], p = 0.007). Quantitative analysis enhanced localization accuracy for both tracers, yielding the greatest improvement for TSPO in gliosis (from 10/41 [24.4%] to 19/41 [46.3%], p = 0.038). CONCLUSION: Dual-tracer PET/MR combined with quantitative analysis may improve subtype-specific presurgical localization in refractory MTLE. TSPO-PET precisely localized the epileptogenic lesion, whereas FDG-PET facilitated differentiation of pathological subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Epilepsy, Temporal LobePositron-Emission TomographyPyrimidinesMagnetic Resonance ImagingPyrazolesHumansFemaleMaleAdultRetrospective StudiesMultimodal ImagingMiddle AgedHippocampal SclerosisYoung AdultRadiopharmaceuticals

Stichwörter der Autor:innen

FluorodeoxyglucosePET/MRPathological subtypeRefractory epilepsyTranslocator protein 18 kDa

Substanzen

Fluorodeoxyglucose F18PyrimidinesN,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)acetamidePyrazolesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
  • Beijing Key Laboratory of Innovation and Translation of Central Nervous System Radiopharmaceuticals, Beijing, 100069, China.
  • Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
  • Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. imaginglu@hotmail.com.
  • Beijing Key Laboratory of Innovation and Translation of Central Nervous System Radiopharmaceuticals, Beijing, 100069, China. imaginglu@hotmail.com.

Förderung

  • National Key Research and Development Program of China
  • Huizhi Ascent Project of Xuanwu Hospital

Zitieren

APA

Zhang, S., Liu, X., Cui, B., Xu, W., Yao, C., Wang, B., Ren, L., & Lu, J. (2026). Quantitative dual-tracer 18F-FDG and 18F-DPA-714 PET/MR for characterizing pathological subtypes in refractory mesial temporal lobe epilepsy. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 7823-7834. https://doi.org/10.1007/s00259-026-08119-3

Vancouver

Zhang S, Liu X, Cui B, Xu W, Yao C, Wang B, et al. Quantitative dual-tracer 18F-FDG and 18F-DPA-714 PET/MR for characterizing pathological subtypes in refractory mesial temporal lobe epilepsy. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):7823-7834. doi:10.1007/s00259-026-08119-3

BibTeX
@article{Zhang2026,
  author = {Zhang, Siqi and Liu, Xiaocao and Cui, Bixiao and Xu, Wenqi and Yao, Chenyang and Wang, Bin and Ren, Liankun and Lu, Jie},
  title = {Quantitative dual-tracer 18F-FDG and 18F-DPA-714 PET/MR for characterizing pathological subtypes in refractory mesial temporal lobe epilepsy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {7823--7834},
  doi = {10.1007/s00259-026-08119-3}
}
Kostenlos starten →